A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
about
Beta-3 adrenergic receptor agonist for adult with overactive bladderNeurophysiology of lower urinary tract function and dysfunctionThe pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseRecent advances in management of bladder overactivity.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladderNew insights into the pharmacology of the bladderβ-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.Prospective pharmacologic therapies for the overactive bladderFunctional and molecular evidence for Kv7 channel subtypes in human detrusor from patients with and without bladder outflow obstruction.Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.Potential therapeutic targets for the treatment of detrusor overactivity.The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder.Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderStimulation of beta3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2+-activated K+ channels.A phase II dose-ranging study of mirabegron in patients with overactive bladderSimilarities and differences in the autonomic control of airway and urinary bladder smooth muscleOn the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the BladderSilodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.Contemporary management of overactive bladder.Neurophysiology and therapeutic receptor targets for stress urinary incontinence.Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.Male lower urinary tract symptoms and α1D-adrenoceptors.Management of benign prostatic hyperplasia with silodosinCritical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.Therapeutic targets for overactive bladder other than smooth muscle.Emerging drugs for overactive bladder.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.A drug safety evaluation of mirabegron in the management of overactive bladder.The Effect of LUTS/BPH and Treatments on Ejaculatory Function.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.New Frontiers of Basic Science Research in Neurogenic Lower Urinary Tract Dysfunction.Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivityExpression of β-Adrenoceptor Subtypes in Urothelium, Interstitial Cells and Detrusor of the Human Urinary Bladder.Correlation Between Bladder Mucosal Alpha-1D/Alpha-1A Adrenoceptor mRNA Ratio and Lower Urinary Tract Function in Benign Prostatic Obstruction Patients.
P2860
Q24187596-31FDC695-DE3D-456B-8468-39F3089CFF68Q24550931-19FCE42E-E356-4357-BCD1-15585D983B36Q26864937-43EBF4A2-82AB-436D-90A5-11405ECD0C1DQ34167658-613330BB-A671-4513-9802-4ABC7904F142Q34405906-B87F0A98-1589-4F30-8A22-E47EE5C4A459Q34468669-AF42C234-6DAB-4F84-A777-1ED6C8999C98Q34931019-E466AE21-FA3D-4C45-BD9A-46DCACC8B069Q35040830-A03BE449-E058-437D-9499-C67DC6C37920Q35049175-032E156E-C3EC-4159-8B21-65B316C917C3Q35076367-781427D6-3DCD-42BB-A6AD-059CABEF4720Q35098568-DD4D58D0-A6B0-4F7B-B8A9-6AF043029D3FQ35545711-7C0775A3-E868-40CF-91AB-B167280A12CBQ35753357-6E3346BF-80A1-4F16-AD98-56142C5749DBQ35807255-0C1A3523-4F4B-4625-A509-B327C8B4F6DBQ36024814-E611C854-6269-49F6-A43D-24CC24402A7AQ36301577-607B36ED-8C39-432D-9BD4-3BCBB6171127Q36573132-8DCCE439-F0D7-413B-A949-A4D5B4ABF241Q36977701-080B9AE8-73F0-43FA-AF63-678EA04DBFA1Q37100337-D365B7E2-9737-4CAB-99B1-598606D7FA67Q37189382-4D768BB2-D274-4673-A446-786E7184311BQ37737698-333FC46C-7459-4120-813A-D11C5292CD74Q37813129-CD8AF6C2-8FA6-48DE-8EF3-79A196720087Q37982213-34228976-65E2-4EAD-B708-D814787F27BCQ37992131-9A1891C0-45AF-4666-8ECC-2E7137B4FA10Q38063330-46486DF2-10E2-4322-981A-CD49305365D7Q38064484-88B6F476-4D0C-4113-9708-205C99DEF3CEQ38160469-6ACF6E6F-C6D0-452A-B3E2-9739617BF7ADQ38193896-E2C15D64-7774-40F8-AA00-C452F7758D32Q38306806-DFE86138-8BD4-4D72-B7AB-FD6617D0A494Q38364035-24994F78-4894-47F7-BCFE-8C43DABC58FDQ38584641-20857B24-D1FA-497F-A3A9-F68BAC9103D4Q38669033-000D7C6D-861C-4272-B088-529C41B7C191Q38765381-1C218D28-F600-435C-81D1-D34DF66FFEC9Q38776115-B6C9D80D-B7F1-4339-A606-4C7AB272D11EQ38815285-1F466E7A-BF0E-4AF9-BF67-93CE9E048F0CQ39046374-2DC32B82-FB35-4387-97FD-13FF529B3470Q39439674-E4937B0B-1587-49A9-BDFF-C6D24CC6FF4FQ39516918-52682F09-BBC5-461E-AD97-58458A3BBBF9Q40215763-2108CF35-43D7-44F0-AA7A-72AD59187B9BQ40215957-32EBA3D7-9195-47CB-8167-03E28EADFFF4
P2860
A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@en
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@nl
type
label
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@en
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@nl
prefLabel
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@en
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@nl
P1476
A quantitative analysis of mRN ...... ormal and obstructed bladders.
@en
P2093
Masanori Nomiya
Osamu Yamaguchi
P304
P356
10.1097/01.JU.0000067621.62736.7C
P407
P433
P577
2003-08-01T00:00:00Z